ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

FDA Gives Accelerated Approval To Tykerb For Metastatic Breast Cancer

February 5, 2010

ACS Division Help Fund Some CIS Offices

September 13, 1985

DCE Board Approves Recompetition Of Two Major Contracts

October 30, 1987

Also in this issue: ODAC Votes To Strip Breast Cancer Indication From Avastin

July 23, 2010

List of core grants renewed in FY 2003, full list of center grants.

January 16, 2004

In Brief: Moorehead Heads ACCC; Anderson President Elect; Segaloff Dies; RAAD Cleveland Clinic Director

March 22, 1985